Advanz Gains Temporary Block On Ocaliva’s Removal From EU Market

 
• By Andrew McConaghie

Despite its legal stay of execution, lack of confirmatory data means the European Commission’s decision for market removal is likely to stand.

Primary Bilary Cholangitis
Ocaliva is for the treatment of the rare liver disease primary biliary cholangitis • Source: Shutterstock

More from Legal & IP

More from Pink Sheet